Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation

Chest

Volumn 123, Issue 6, 2003, Pages 1825-1831

  Chalermskulrat, Worakij ^a   Neuringer, Isabel P ^a   Schmitz, John L ^b   Catellier, Diane J ^b   Gurka, Matthew J ^b   Randell, Scott H ^a   Aris, Robert M ^a,b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiolitis obliterans syndrome; Human leukocyte associated antigen; Lung transplant; Obliterative bronchiolitis

Indexed keywords

CYCLOSPORIN A; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN;

ADULT; AGE; AIRWAY; ALLOIMMUNITY; ARTICLE; BRONCHIOLITIS; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DONOR; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS; LUNG FUNCTION; LUNG INJURY; LUNG TRANSPLANTATION; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR;

EID: 0038128589     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.6.1825     Document Type: Article

References (29)

1. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report; 2001. J Heart Lung Transplant 2001; 20:805-815
2. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts: International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12:713-716
3. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297-310
4. Wisser W, Wekerle T, Zlabinger G, et al. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant 1996; 15:1209-1216
5. Iwaki Y, Yoshida Y, Griffith B. The HLA matching effect in lung transplantation. Transplantation 1993; 56:1528-1529
6. Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995; 109:49-57
7. Quantz MA, Bennett LE, Meyer DM, et al. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19:473-479
8. Schulman LL, Weinberg AD, McGregor C, et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157:1833-1837
9. Keogh A, Kaan A, Doran T, et al. HLA mismatching and outcome in heart, heart-lung, and single lung transplantation. J Heart Lung Transplant 1995; 14:444-451
10. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65:648-653
11. Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114:195-202
12. Schulman LL, Weinberg AD, McGregor CC, et al. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001; 163:437-442
13. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18:828-837
14. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15:1200-1208
15. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999; 159:829-833
16. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17:1255-1263
17. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110:4-13
18. Flume PA, Egan TM, Paradowski LJ, et al. Infections complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149:1601-1607
19. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154:1712-1717
20. American Thoracic Society. Standardization of spirometry: 1987 update; statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136:1285-1298
21. American Thoracic Society. Standardization of spirometry: 1994 update; American Thoracic Society. Am J Respir Crit Care Med 1995; 152:1107-1136
22. Hopkins K. The basic lymphocyte microcytotoxicity tests. In: Phelan D, Mickelson EM, Noreen HS, et al, eds. The ASHI laboratory manual (vol I. B. 1.1). Lexana, KS: The American Society for Histocompatibility and Immunogenetics, 1993
23. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1-15
24. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS System. Cary, NC: SAS Institute, 2000
25. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67:1155-1161
26. SivaSai KS, Smith MA, Poindexter NJ, et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999; 67:1094-1098
27. Gammie JS, Stukus DR, Pham SM, et al. Effect of ischemic time on survival in clinical lung transplantation. Ann Thorac Surg 1999; 68:2015-2019
28. Novick RJ, Bennett LE, Meyer DM, et al. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425-431
29. Haider Y, Yonan N, Mogulkoc N, et al. Bronchiolitis obliterans syndrome in single lung transplant recipients: patients with emphysema versus patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant 2002; 21:327-333